(Press-News.org) Hypertension impairs blood vessels, neurons and white matter in the brain well before the condition causes a measurable rise in blood pressure, according to a new preclinical study from Weill Cornell Medicine investigators. The changes help explain why hypertension is a major risk factor for developing cognitive disorders, such as vascular cognitive impairment and Alzheimer’s disease.
The preclinical findings, published Nov. 14 in Neuron, reveal that hypertension may induce early gene expression changes in individual brain cells that could interfere with thinking and memory. The findings may lead to medications that both reduce blood pressure and prevent cognitive decline.
Patients with hypertension have a 1.2 to 1.5-fold higher risk of developing cognitive disorders than people without the condition, but exactly why is not understood. While many current hypertension medications successfully lower high blood pressure, they often show little or no effect on brain function. This suggests blood vessel changes could cause damage independently of the elevated pressure associated with hypertension.
“We found that the major cells responsible for cognitive impairment were affected just three days after inducing hypertension in mice—before blood pressure increased,” said senior author Dr. Costantino Iadecola, director of the Feil Family Brain and Mind Research Institute, professor of neuroscience and Anne Parrish Titzell Professor of Neurology at Weill Cornell. “The bottom line is something beyond the dysregulation of blood pressure is involved.”
Dr. Anthony Pacholko, postdoctoral associate in neuroscience at Weill Cornell, co-led the work.
Aging Too Soon
In previous work, Dr. Iadecola’s team found that hypertension affects the function of neurons globally, but recent innovations in single-cell technologies have allowed them to zero in on what is happening in the different types of cells in the brain at the molecular level.
To induce hypertension in mice, the researchers administered the hormone angiotensin, which raises blood pressure, mimicking what happens in humans. Then, they looked at how different types of brain cells were impacted three days later (before blood pressure increased) and after 42 days (when blood pressure was high, and cognition was affected).
At day three, gene expression dramatically changed in three cell types: endothelial cells, interneurons and oligodendrocytes. Endothelial cells, which line the internal surface of blood vessels, aged prematurely with lower energy metabolism and higher senescence markers. The researchers also observed early signs of a weakened blood-brain barrier, which regulates the influx of nutrients into the brain and keeps out harmful molecules. Interneurons, brain cells that regulate the balance of excitatory and inhibitory nerve signals, were damaged, leading to an imbalance between inhibition and excitation like that seen in Alzheimer’s disease.
In addition, oligodendrocytes that enrobe nerve fibers with myelin did not properly express genes responsible for their maintenance and replacement. Without enough oligodendrocytes to maintain the health of the myelin sheath, neurons eventually lose the ability to communicate with each other, which is critical for cognitive function. Even more gene expression changes were observed at day 42, coinciding with cognitive decline.
“The extent of the early alterations induced by hypertension was quite surprising,” Dr. Pacholko said. “Understanding how hypertension affects the brain at the cellular and molecular levels during the earliest stages of the disease may provide clues to finding ways that can potentially block neurodegeneration.”
Moving Forward
An anti-hypertensive drug already in clinical use called losartan inhibits the angiotensin receptor. “In some human studies, the data suggest that the angiotensin receptor inhibitors may be more beneficial to cognitive health than other drugs that lower blood pressure,” Dr. Iadecola said. In additional experiments, losartan reversed the early effects of hypertension on endothelial cells and interneurons in the mouse model.
“Hypertension is a leading cause of damage to the heart and the kidneys, that can be prevented by antihypertensive drugs. So independent of cognitive function, treating high blood pressure is a priority,” Dr. Iadecola said.
Dr. Iadecola and his team are now investigating how the premature aging of small blood vessels induced by hypertension could trigger interneuron and oligodendrocyte defects. And in due time, the researchers hope to uncover the best way to prevent or reverse the devastating effects of hypertension on cognitive function.
Many Weill Cornell Medicine physicians and scientists maintain relationships and collaborate with external organizations to foster scientific innovation and provide expert guidance. The institution makes these disclosures public to ensure transparency. For this information, please see the profile for Dr. Costantino Iadecola.
END
Hypertension affects the brain much earlier than expected
2025-11-14
ELSE PRESS RELEASES FROM THIS DATE:
Nonlinear association between systemic immune-inflammation index and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease and atrial fibrillation: a cross-sectio
2025-11-14
Background: Chronic obstructive pulmonary disease (COPD) and atrial fibrillation (AF) frequently coexist, and their concurrence is associated with worse clinical outcomes than either condition alone. Inflammation plays a central role in the pathogenesis of both diseases. The systemic immune-inflammation index (SII), derived from neutrophil, platelet, and lymphocyte counts, has emerged as a promising marker reflecting systemic inflammation. However, its prognostic value in critically ill patients with concurrent COPD and AF remains unclear. This study aimed to investigate the association between SII and in-hospital mortality in intensive care unit (ICU) ...
Drift logs destroying intertidal ecosystems
2025-11-14
Logs are a familiar sight on the beaches along the coast of Vancouver Island and Haida Gwaii and are often viewed positively, as they can stabilize the banks, be used for firewood or act as benches by beach-goers. However, new research from the University of Victoria (UVic) shows that these logs are not as innocuous as they seem.
According to a study published by UVic biologist Tom Reimchen and two of his students, free-floating logs that wash ashore, referred to as drift logs, are causing widespread destruction of rocky intertidal ecosystems communities along the coast of Western Canada.
“In this study, we looked at both the ecological impact of drift ...
New test could speed detection of three serious regional fungal infections
2025-11-14
ROCKVILLE, Md. — Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil exposure. These infections can affect both healthy and immunocompromised people, but proper diagnosis remains slow, which delays treatment.
The current gold standard for making a diagnosis relies on fungal culturing, which can take weeks, and tests that look for antigens, which lack specificity, or antibodies in the blood, which are often unreliable in early disease. But now researchers from Indiana University Health and the IU School of Medicine have developed a new molecular test capable of detecting ...
New research on AI as a diagnostic tool to be featured at AMP 2025
2025-11-14
Artificial intelligence is being utilized across a variety of industries to reduce human workload, speed up workflows and improve output. Within the field of molecular pathology, AI is being used in part to improve diagnostic processes and accuracy. AI has the potential to not only automate tasks, but also to enhance clinical decision making.
Innovative studies in diagnostic applications of artificial intelligence will be presented at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, taking place Nov. 11–15 in Boston.
Journalists are invited to attend the meeting in person or sign up for online access ...
New test could allow for more accurate Lyme disease diagnosis
2025-11-14
Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately than traditional testing methods.
Over the past 30 years, Lyme disease has been on the rise in the United States, particularly in the Northeast region, where ticks carrying the bacterium Borrelia burgdorferi are active from late spring through early fall. If left untreated, Lyme disease can cause joint, heart and nervous system complications.
While the characteristic bull’s eye-like rash is an early sign of the disease, it occurs in only about 25% of patients. Many patients develop skin lesions mimicking other illnesses, complicating ...
New genetic tool reveals chromosome changes linked to pregnancy loss
2025-11-14
Pregnancy loss may occur in as many as 25% of all pregnancies. Most of these losses occur in the first trimester, and about half are caused by genetic or chromosomal issues.
When pregnancy loss occurs three or more times, the losses are referred to as recurrent. Often the cause of recurrent pregnancy loss is difficult to uncover and remains unknown to those experiencing it.
However, two new studies presented at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, taking place Nov. 11–15 in Boston, provide some answers.
These studies both utilized a cutting-edge technique known as optical ...
New research in blood cancer diagnostics to be featured at AMP 2025
2025-11-14
ROCKVILLE, Md. — Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It develops quickly, with symptoms often coming on within just a few weeks, and requires urgent treatment. Despite advances, many patients relapse and outcomes can be poor — making faster, more accurate diagnostic tools critical to patient survival.
Breakthrough studies in hematopathology — including advances in genetic testing, relapse prediction and detection of hidden, disease-defining gene fusions in AML — will be presented at the Association for Molecular Pathology (AMP) 2025 Annual Meeting & Expo, taking place Nov. 11–15 ...
Analysis reveals that imaging is overused in diagnosing and managing the facial paralysis disorder Bell’s palsy
2025-11-14
Journal: The Laryngoscope
Title: Nationwide Analysis of Head and Neck Imaging for Bell’s palsy: Insights from Healthcare Claims
Authors: Sujay Ratna, MD Candidate, Icahn School of Medicine at Mount Sinai
Mingyang Gray, MD, MPH, Assistant Professor of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai
Bottom line: This study analyzes how imaging is used to diagnose and manage Bell’s palsy, a condition that causes sudden weakness ...
Research progress on leptin in metabolic dysfunction-associated fatty liver disease
2025-11-14
Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with obesity, type 2 diabetes (T2DM), and metabolic syndrome. Its pathogenesis is complex, following a "multiple-hit" hypothesis that involves triglyceride accumulation, insulin resistance (IR), lipotoxicity, chronic inflammation, and oxidative stress. Among the various adipokines implicated, leptin, a hormone central to energy homeostasis, has been identified ...
Fondazione Telethon announces CHMP positive opinion for Waskyra™, a gene therapy for the treatment of Wiskott-Aldrich syndrome (WAS)
2025-11-14
Fondazione Telethon announces the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorisation in the European Union for Waskyra™, an ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency.
Fondazione Telethon is the first non-profit organization to have successfully led the full pathway from laboratory research to regulatory approval, collaborating with industry partners when available to bring gene therapies from discovery to patients.
Developed through decades of research at ...